{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:23:03Z","timestamp":1791883383621,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7647","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1038\/nature21702","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T19:01:29Z","timestamp":1490122889000},"page":"733-737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":603,"title":["The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1"],"prefix":"10.1038","volume":"543","author":[{"given":"Andrew A.","family":"Wylie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Schoepfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Jahnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra W.","family":"Cowan-Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Furet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas L.","family":"Marzinzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Buonamici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Quamrul","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Berellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Thohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Bitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilli","family":"Petruzzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Gary","family":"Vanasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Warmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,22]]},"reference":[{"key":"BFnature21702_CR1","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti, L. et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29, 1123\u20131132 (2015)","journal-title":"Leukemia"},{"key":"BFnature21702_CR2","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1158\/1078-0432.CCR-10-2922","volume":"17","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian, H. M., Baccarani, M., Jabbour, E., Saglio, G. & Cortes, J. E. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin. Cancer Res. 17, 1674\u20131683 (2011)","journal-title":"Clin. Cancer Res."},{"key":"BFnature21702_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029\u20131035 (2010)","journal-title":"Lancet Oncol."},{"key":"BFnature21702_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross, D. M. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122, 515\u2013522 (2013)","journal-title":"Blood"},{"key":"BFnature21702_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nchembio760","volume":"2","author":"FJ Adri\u00e1n","year":"2006","unstructured":"Adri\u00e1n, F. J. et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2, 95\u2013102 (2006)","journal-title":"Nat. Chem. Biol."},{"key":"BFnature21702_CR6","doi-asserted-by":"publisher","first-page":"7043","DOI":"10.1021\/ja101837n","volume":"132","author":"W Jahnke","year":"2010","unstructured":"Jahnke, W. et al. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J. Am. Chem. Soc. 132, 7043\u20137048 (2010)","journal-title":"J. Am. Chem. Soc."},{"key":"BFnature21702_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature08675","volume":"463","author":"J Zhang","year":"2010","unstructured":"Zhang, J. et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501\u2013506 (2010)","journal-title":"Nature"},{"key":"BFnature21702_CR8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","volume":"112","author":"O Hantschel","year":"2003","unstructured":"Hantschel, O. et al. A myristoyl\/phosphotyrosine switch regulates c-Abl. Cell 112, 845\u2013857 (2003)","journal-title":"Cell"},{"key":"BFnature21702_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","volume":"112","author":"B Nagar","year":"2003","unstructured":"Nagar, B. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859\u2013871 (2003)","journal-title":"Cell"},{"key":"BFnature21702_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012)","journal-title":"Nature"},{"key":"BFnature21702_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"1804","author":"PW Manley","year":"2010","unstructured":"Manley, P. W. et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim. Biophys. Acta 1804, 445\u2013453 (2010)","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnature21702_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nm.3841","volume":"21","author":"HE Bhang","year":"2015","unstructured":"Bhang, H. E. et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21, 440\u2013448 (2015)","journal-title":"Nat. Med."},{"key":"BFnature21702_CR13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood.V126.23.138.138","volume":"126","author":"OG Ottmann","year":"2015","unstructured":"Ottmann, O. G. et al. ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single-agent activity in a phase I study of patients with CML with failure of prior TKI therapy. Blood 126, 138 (2015)","journal-title":"Blood"},{"key":"BFnature21702_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/clpt.2009.208","volume":"87","author":"C Tanaka","year":"2010","unstructured":"Tanaka, C. et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin. Pharmacol. Ther. 87, 197\u2013203 (2010)","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnature21702_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1146\/annurev.biochem.69.1.497","volume":"69","author":"TA Kunkel","year":"2000","unstructured":"Kunkel, T. A. & Bebenek, K. DNA replication fidelity. Annu. Rev. Biochem. 69, 497\u2013529 (2000)","journal-title":"Annu. Rev. Biochem."},{"key":"BFnature21702_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/cncr.25604","volume":"117","author":"A Al-Kali","year":"2011","unstructured":"Al-Kali, A. et al. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 117, 327\u2013335 (2011)","journal-title":"Cancer"},{"key":"BFnature21702_CR17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin, D. et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J. Clin. Oncol. 30, 232\u2013238 (2012)","journal-title":"J. Clin. Oncol."},{"key":"BFnature21702_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford, S. et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 124, 511\u2013518 (2014)","journal-title":"Blood"},{"key":"BFnature21702_CR19","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein, B. et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26, 2096\u20132102 (2012)","journal-title":"Leukemia"},{"key":"BFnature21702_CR20","doi-asserted-by":"publisher","first-page":"e00747","DOI":"10.7554\/eLife.00747","volume":"2","author":"I Bozic","year":"2013","unstructured":"Bozic, I. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2, e00747 (2013)","journal-title":"eLife"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature21702.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature21702","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature21702.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:00:34Z","timestamp":1684418434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature21702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":20,"journal-issue":{"issue":"7647","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["BFnature21702"],"URL":"https:\/\/doi.org\/10.1038\/nature21702","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727429677.793530085","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.727429677.793541210","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"9 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2017","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the key to Figure 3b, \u2018CME911\u2019 was replaced with \u2018ABL001\u2019.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}